Cardiff Oncology (CRDF) Earnings Date & Reports

Key Takeaways

• Cardiff Oncology (CRDF) is expected to report third-quarter 2026 results in early November, with Wall Street consensus projecting a net loss of roughly $0.14 to $0.16 per share.
• Analysts model minimal royalty revenue near $80,000 for the period, reflecting the company's pre-commercial, clinical-stage profile.
• Investors are watching the company's cash runway closely, given that management has signaled it will need additional capital to fund the planned CRDF-005 Phase 3 registrational study.
• The lead program, onvansertib in first-line RAS-mutated metastatic colorectal cancer (mCRC), remains the central catalyst after a successful End-of-Phase 2 meeting with the FDA earlier in 2026.
• For more on the latest company developments, visit the Major News page, track Today's Price Move, review analyst Price Targets, and explore the Forecast pages.
• Looking for additional trading ideas? Explore Trending AI Robots to see AI-driven strategies currently drawing market attention.

Earnings Context and Why It Matters

For a clinical-stage biotechnology company such as Cardiff Oncology, quarterly earnings are less about revenue and more about capital discipline and clinical execution. The company generates only modest royalty income from assets unrelated to its lead drug candidate, so investors focus on operating-expense trends, the cash balance, and progress toward pivotal clinical milestones. Prior quarters have shown a narrowing net loss as research and development (R&D) spending declined following the completion of the randomized Phase 2 CRDF-004 trial. With a Phase 3 registrational study now on the horizon, this report offers a timely window into how management is balancing spending against a runway that currently extends into 2027.

Earnings Expectations

Consensus estimates for Cardiff Oncology's third quarter of 2026 point to a net loss of approximately $0.14 per share, with individual analyst projections ranging from about $0.13 to $0.20 per share. Royalty revenue is expected to remain minimal, with estimates clustering near $80,000. By comparison, the company reported a net loss of $0.14 per share in the second quarter of 2026, beating the consensus estimate of $0.16, on revenue of roughly $104,000. In the first quarter of 2026, the net loss was $0.18 per share on revenue of $41,000, coming in below expectations. Investors will be watching whether the downward trend in R&D spending continues and whether management provides updated guidance on the timing and cost of the planned Phase 3 trial.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is built to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, helping investors identify setups across sectors including biotechnology. Explore the AI Screener to see how AI-powered filtering can sharpen your research process.

Market Reaction and Investor Sentiment

Sentiment heading into Cardiff Oncology's third-quarter print centers on clinical progress rather than financial performance. The stock has historically reacted to data milestones — most notably the positive update from the randomized Phase 2 CRDF-004 trial of onvansertib in first-line RAS-mutated mCRC — more than to the modest earnings miss or beat. In April 2026, the company announced a successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), during which it aligned on key design elements for a Phase 3 registrational trial. Key risk factors heading into the report include the timing and cost of that pivotal study, potential dilution from future capital raises, and any changes to the cash-runway guidance. Investors will also listen for updates on investigator-initiated studies across other cancer indications.

Forward Outlook and Key Factors to Monitor

The most important forward-looking item is the design and initiation of the CRDF-005 Phase 3 registrational study for onvansertib in first-line RAS-mutated mCRC. Management has said it plans to share additional Phase 3 details and its regulatory strategy, and any update on trial timelines, sites, or enrollment plans could meaningfully shape investor expectations.

Capital allocation is another central theme. The company ended the first quarter of 2026 with approximately $46.1 million in cash, cash equivalents, and short-term investments, and subsequently completed a financing that management indicated would extend the runway into the third quarter of 2027. Because the Phase 3 program will require additional capital, investors should monitor operating-expense trends and any commentary on future funding needs.

Finally, watch for data catalysts beyond the lead program. Updated CRDF-004 results presented at major oncology meetings, along with preclinical work combining onvansertib with antibody-drug conjugates and ongoing investigator-initiated trials in pancreatic, lung, and breast cancers, could broaden the company's clinical narrative. Operating-expense discipline and clinical execution will likely remain the key drivers of investor sentiment in the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations